Engineering Cell Therapies. Redefining Patient Outcomes.
AdopTracell is developing next-generation autoimmune therapies with the potential to profoundly improve patient outcomes.
Engineering Cell Therapies. Redefining Patient Outcomes.
AdopTracell is developing next-generation autoimmune therapies with the potential to profoundly improve patient outcomes.
Our powerful platform simplifies complex immunological dysregulation using nature’s road map.
Uncontrolled immune function affects people in many different ways — from allergies to autoimmune diseases to transplant rejections.
We are developing an innovative technology with the capability to regulate the immune system and restore immune homeostasis through the use of genetically-engineered chimeric antigen receptor (CAR) immune regulatory T-cells (Tregs). These purposefully designed cells counteract toxic immune cells and allow for healing.
Our Platform
This platform delivers best-in-class regulatory T-cell therapies that could transform care for challenging autoimmune conditions.
The result is a highly differentiated, autologous Treg therapy customized for each patient.
A simple, outpatient procedure can enable durable immune control, and could be more cost-effective than currently used chronic therapies, which do not prevent life-shortening complications.
Our goal: to redefine life-altering autoimmune diseases into controlled, immune conditions.
Therapeutic Focus
Genetically-engineered Treg therapies offer precise immune regulation, potentially redefining care for a wide range of autoimmune diseases.
For example, this approach could reverse Type 1 diabetes by healing insulin-producing beta cells that are destroyed by the immune system. Compelling early data in humanized animal models and in-vitro experiments using human tissues have indicated the potential for disease reversal.
Our Pipeline:
About AdopTracell
The right team, the right science, and the right location with Ohio’s growing competitiveness in gene and cell therapy.
We’re a diverse group of academic physicians, life-scientists, bioengineers, and entrepreneurs with the precise combination of expertise, ingenuity, and resolve to transform promising science into real cures.
Our development efforts are funded by grants (among others) from the Ohio State University iCorps and the Ohio Department of Development’s Technology Validation and Start-up Fund (TVSF).
